8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Feb 5, 2026·SEC
Prestige Consumer Healthcare Inc.(PBH)Earnings, Financials & Key Ratios
PBH•NYSE
12.0× P/E·Price updated Jun 19, 2026
AboutPrestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.Show more
- Revenue$1.09B-4.3%
- EBITDA$341M-7.2%
- Net Income$190M-11.3%
- EPS (Diluted)3.91-8.9%
- Gross Margin52.78%-5.3%
- EBITDA Margin31.29%-3.0%
- Operating Margin28.42%-4.0%
- Net Margin17.48%-7.3%
- ROE10.22%-16.9%
PBH Key Insights
Prestige Consumer Healthcare Inc. (PBH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 23.4% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 2.7% through buybacks
- ✓Healthy 5Y average net margin of 13.3%
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗Weak momentum: RS Rating 20 (bottom 20%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PBH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PBH Price & Volume
Prestige Consumer Healthcare Inc. (PBH) stock price & volume — 10-year historical chart
Loading chart...
PBH Growth Metrics
Prestige Consumer Healthcare Inc. (PBH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years3.05%
5 Years2.91%
3 Years-1.17%
TTM-4.31%
Profit CAGR
10 Years6.66%
5 Years2.93%
3 Years-
TTM-11.33%
EPS CAGR
10 Years7.6%
5 Years3.77%
3 Years-
TTM-8.86%
Return on Capital
10 Years7.09%
5 Years7.85%
3 Years10.09%
Last Year9.21%
PBH Recent Earnings
Prestige Consumer Healthcare Inc. (PBH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$1.23-11.5%
$1.39
Rev
$282M-4.1%
$294M
Q1 2026
Feb 5, 2026Metric
Actual
Est
EPS
$1.14-1.7%
$1.16
Rev
$283M+0.4%
$282M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.07+10.3%
$0.97
Rev
$274M-6.8%
$294M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.95-5.9%
$1.01
Rev
$250M-9.3%
$275M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $1.23vs $1.39-11.5% | $282Mvs $294M-4.1% |
| Q1 2026 | Feb 5, 2026 | $1.14vs $1.16-1.7% | $283Mvs $282M+0.4% |
| Q4 2025 | Nov 6, 2025 | $1.07vs $0.97+10.3% | $274Mvs $294M-6.8% |
| Q3 2025 | Aug 7, 2025 | $0.95vs $1.01-5.9% | $250Mvs $275M-9.3% |
Based on last 12 quarters of dataView full earnings history →
PBH Peer Comparison
Prestige Consumer Healthcare Inc. (PBH) competitors in Drug Wholesalers and Distributors — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SPB | 1.95B | 83.97 | 21.75 | -5.23% | 4.48% | 6.65% | 0.34 | |
 CHD | 22.65B | 95.64 | 31.67 | 1.57% | 11.81% | 17.45% | 0.55 | |
 ENR | 1.47B | 21.52 | 6.48 | 2.28% | 6.55% | 116.9% | 20.79 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 COTY | 1.72B | 1.95 | -4.43 | -3.68% | -9.26% | -14.13% | 1.07 | |
 KVUE | 34.79B | 18.12 | 23.84 | -2.14% | 10.61% | 15.18% | 0.79 | |
 HLN | 39.9B | 8.96 | 18.73 | -3.96% | 14.46% | 19.9% | 0.52 | |
 HIMS | 7.79B | 35.47 | 69.55 | 59% | -0.56% | -2.48% | 2.34 |
Compare PBH vs Peers
Prestige Consumer Healthcare Inc. (PBH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PBH Income Statement
Prestige Consumer Healthcare Inc. (PBH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.04B | 975.78M | 963.01M | 943.37M | 1.09B | 1.13B | 1.13B | 1.14B | 1.09B |
Revenue Growth % | 18.04% | -6.28% | -1.31% | -2.04% | 15.21% | 3.76% | -0.21% | 1.1% | -4.31% |
Cost of Goods Sold | 464.67M | 420.2M | 410.79M | 395.89M | 466.17M | 502.43M | 500.91M | 503.3M | 514.07M |
COGS % of Revenue | 44.63% | 43.06% | 42.66% | 41.97% | 42.89% | 44.55% | 44.51% | 44.24% | 47.22% |
Gross Profit | 576.5M▲ 0% | 555.58M▼ 3.6% | 552.22M▼ 0.6% | 547.47M▼ 0.9% | 620.65M▲ 13.4% | 625.29M▲ 0.7% | 624.45M▼ 0.1% | 634.46M▲ 1.6% | 574.64M▼ 9.4% |
Gross Margin % | 55.37% | 56.94% | 57.34% | 58.03% | 57.11% | 55.45% | 55.49% | 55.76% | 52.78% |
Gross Profit Growth % | 15.24% | -3.63% | -0.6% | -0.86% | 13.37% | 0.75% | -0.14% | 1.6% | -9.43% |
Operating Expenses | 360.64M | 259.9M | 261.07M | 250.07M | 290.73M | 647.71M | 282.02M | 297.69M | 265.23M |
OpEx % of Revenue | 34.64% | 26.63% | 27.11% | 26.51% | 26.75% | 57.44% | 25.06% | 26.16% | 24.36% |
Selling, General & Admin | 332.21M | 232.85M | 236.31M | 223.69M | 264.8M | 252.41M | 259.47M | 263.93M | 265.23M |
SG&A % of Revenue | 31.91% | 23.86% | 24.54% | 23.71% | 24.37% | 22.38% | 23.06% | 23.2% | 24.36% |
Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 28.43M | -476K | 24.76M | 26.38M | 25.93M | 395.29M | 22.55M | 33.76M | 0 |
Operating Income | 215.87M▲ 0% | 67.5M▼ 68.7% | 291.15M▲ 331.3% | 297.4M▲ 2.1% | 329.92M▲ 10.9% | -22.41M▼ 106.8% | 342.43M▲ 1627.7% | 336.77M▼ 1.7% | 309.41M▼ 8.1% |
Operating Margin % | 20.73% | 6.92% | 30.23% | 31.53% | 30.36% | -1.99% | 30.43% | 29.6% | 28.42% |
Operating Income Growth % | 4.99% | -68.73% | 331.32% | 2.15% | 10.93% | -106.79% | 1627.68% | -1.65% | -8.13% |
EBITDA | 249.29M | 99.28M | 328.94M | 327.57M | 362.01M | 10.21M | 373.1M | 366.95M | 340.68M |
EBITDA Margin % | 23.94% | 10.17% | 34.16% | 34.72% | 33.31% | 0.91% | 33.15% | 32.25% | 31.29% |
EBITDA Growth % | 7.73% | -60.17% | 231.31% | -0.42% | 10.52% | -97.18% | 3554.3% | -1.65% | -7.16% |
D&A (Non-Cash Add-back) | 33.43M | 31.78M | 37.78M | 30.16M | 32.09M | 32.63M | 30.68M | 30.17M | 31.27M |
EBIT | 322.3M | 67.03M | 287.72M | 286.44M | 326.75M | -24.75M | 343.19M | 331.82M | 309.41M |
Net Interest Income | -105.88M | -105.08M | -96.22M | -82.33M | -64.29M | -69.16M | -67.16M | -47.63M | -42.34M |
Interest Income | 388K | 217K | 342K | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 106.27M | 105.3M | 96.57M | 82.33M | 64.29M | 69.16M | 67.16M | 47.63M | 42.34M |
Other Income/Expense | -108.39M | -105.56M | -100M | -93.29M | -67.46M | -71.5M | -66.4M | -52.59M | -51.91M |
Pretax Income | 107.09M▲ 0% | -38.05M▼ 135.5% | 191.15M▲ 602.3% | 204.11M▲ 6.8% | 262.46M▲ 28.6% | -93.92M▼ 135.8% | 276.02M▲ 393.9% | 284.19M▲ 3.0% | 257.5M▼ 9.4% |
Pretax Margin % | 10.29% | -3.9% | 19.85% | 21.64% | 24.15% | -8.33% | 24.53% | 24.98% | 23.65% |
Income Tax | -232.48M | -2.25M | 48.87M | 39.43M | 57.08M | -11.61M | 66.69M | 69.58M | 67.19M |
Effective Tax Rate % | -217.1% | 5.93% | 25.57% | 19.32% | 21.75% | 12.36% | 24.16% | 24.49% | 26.1% |
Net Income | 339.57M▲ 0% | -35.8M▼ 110.5% | 142.28M▲ 497.4% | 164.68M▲ 15.7% | 205.38M▲ 24.7% | -82.31M▼ 140.1% | 209.34M▲ 354.3% | 214.6M▲ 2.5% | 190.3M▼ 11.3% |
Net Margin % | 32.61% | -3.67% | 14.77% | 17.46% | 18.9% | -7.3% | 18.6% | 18.86% | 17.48% |
Net Income Growth % | 389.33% | -110.54% | 497.43% | 15.74% | 24.71% | -140.07% | 354.34% | 2.52% | -11.33% |
Net Income (Continuing) | 339.57M | -35.8M | 142.28M | 164.68M | 205.38M | -82.31M | 209.34M | 214.6M | 190.3M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 6.34▲ 0% | -0.69▼ 110.9% | 2.78▲ 502.9% | 3.25▲ 16.9% | 4.04▲ 24.3% | -1.65▼ 140.8% | 4.17▲ 352.7% | 4.29▲ 2.9% | 3.91▼ 8.9% |
EPS Growth % | 387.69% | -110.88% | 502.9% | 16.91% | 24.31% | -140.84% | 352.73% | 2.88% | -8.86% |
EPS (Basic) | 6.34 | -0.69 | 2.81 | 3.28 | 4.09 | -1.65 | 4.21 | 4.32 | 3.93 |
Diluted Shares Outstanding | 53.53M | 52.07M | 51.14M | 50.6M | 50.84M | 49.89M | 50.18M | 50.08M | 48.72M |
Basic Shares Outstanding | 53.1M | 51.88M | 50.72M | 50.21M | 50.26M | 49.88M | 49.76M | 49.7M | 48.46M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PBH Balance Sheet
Prestige Consumer Healthcare Inc. (PBH) balance sheet — assets, liabilities & shareholders' equity
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 303.48M | 300.94M | 365.65M | 269.83M | 293.27M | 391.74M | 375.04M | 448.33M | 431.48M |
Cash & Short-Term Investments | 32.55M | 27.53M | 94.76M | 32.3M | 27.18M | 58.49M | 46.47M | 97.88M | 63.87M |
Cash Only | 32.55M | 27.53M | 94.76M | 32.3M | 27.18M | 58.49M | 46.47M | 97.88M | 63.87M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 140.88M | 148.79M | 150.52M | 114.67M | 139.33M | 167.02M | 176.78M | 194.29M | 191.92M |
Days Sales Outstanding | 49.39 | 55.66 | 57.05 | 44.37 | 46.79 | 54.06 | 57.34 | 62.33 | 64.34 |
Inventory | 118.55M | 119.88M | 116.03M | 114.96M | 120.34M | 162.12M | 138.72M | 147.71M | 159.13M |
Days Inventory Outstanding | 93.12 | 104.13 | 103.09 | 105.99 | 94.23 | 117.78 | 101.08 | 107.12 | 112.99 |
Other Current Assets | 0 | 4.74M | 0 | 0 | 0 | 4.12M | 13.08M | 8.44M | 16.56M |
Total Non-Current Assets | 3.46B | 3.14B | 3.15B | 3.16B | 3.38B | 2.96B | 2.94B | 2.95B | 3.12B |
Property, Plant & Equipment | 52.55M | 51.18M | 90.72M | 102.77M | 98.53M | 89.53M | 89.33M | 127.84M | 171.25M |
Fixed Asset Turnover | 19.81x | 19.07x | 10.62x | 9.18x | 11.03x | 12.60x | 12.60x | 8.90x | 6.36x |
Goodwill | 620.1M | 578.58M | 575.18M | 578.08M | 578.98M | 527.55M | 527.73M | 527.42M | 581.11M |
Intangible Assets | 2.78B | 2.51B | 2.48B | 2.48B | 2.7B | 2.34B | 2.32B | 2.3B | 2.3B |
Long-Term Investments | -26K | -399.57M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 3.57M | 3.13M | 2.96M | 2.86M | 3.27M | 3M | 5.72M | 3.27M | 2.17M |
Total Assets | 3.76B▲ 0% | 3.44B▼ 8.5% | 3.51B▲ 2.1% | 3.43B▼ 2.4% | 3.67B▲ 7.0% | 3.35B▼ 8.6% | 3.32B▼ 1.1% | 3.4B▲ 2.5% | 3.55B▲ 4.3% |
Asset Turnover | 0.28x | 0.28x | 0.27x | 0.28x | 0.30x | 0.34x | 0.34x | 0.33x | 0.31x |
Asset Growth % | -3.85% | -8.5% | 2.12% | -2.41% | 7.04% | -8.63% | -1.05% | 2.53% | 4.27% |
Total Current Liabilities | 123.2M | 126.98M | 149.88M | 122.14M | 143.42M | 160.72M | 117.05M | 106.62M | 120.92M |
Accounts Payable | 61.39M | 56.56M | 62.38M | 45.98M | 55.76M | 62.74M | 38.98M | 18.93M | 22.79M |
Days Payables Outstanding | 48.22 | 49.13 | 55.42 | 42.39 | 43.66 | 45.58 | 28.4 | 13.72 | 16.18 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.55M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.9M | 88K | 13.39M | 14.07M | 19.59M | 14.29M | 57.13M | 14.21M | 72.72M |
Current Ratio | 2.46x | 2.37x | 2.44x | 2.21x | 2.04x | 2.44x | 3.20x | 4.20x | 3.57x |
Quick Ratio | 1.50x | 1.43x | 1.67x | 1.27x | 1.21x | 1.43x | 2.02x | 2.82x | 2.25x |
Cash Conversion Cycle | 94.28 | 110.66 | 104.72 | 107.97 | 97.36 | 126.25 | 130.01 | 155.73 | 161.15 |
Total Non-Current Liabilities | 2.46B | 2.22B | 2.19B | 1.95B | 1.95B | 1.75B | 1.55B | 1.46B | 1.54B |
Long-Term Debt | 1.99B | 1.8B | 1.73B | 1.48B | 1.48B | 1.35B | 1.13B | 992.36M | 993.95M |
Capital Lease Obligations | 0 | 0 | 29.5M | 26.52M | 20.59M | 11.54M | 7.7M | 43.36M | 38.92M |
Deferred Tax Liabilities | 442.52M | 399.57M | 407.81M | 434.05M | 444.92M | 380.43M | 403.6M | 419.59M | 500.67M |
Other Non-Current Liabilities | 23.33M | 20.05M | 25.44M | 8.61M | 7.48M | 8.16M | 9.19M | 5.39M | 5.58M |
Total Liabilities | 2.58B | 2.35B | 2.34B | 2.07B | 2.09B | 1.91B | 1.66B | 1.57B | 1.66B |
Total Debt | 1.99B | 1.8B | 1.77B | 1.51B | 1.51B | 1.37B | 1.14B | 1.04B | 1.05B |
Net Debt | 1.96B | 1.77B | 1.67B | 1.48B | 1.48B | 1.31B | 1.09B | 946.37M | 981.56M |
Debt / Equity | 1.69x | 1.64x | 1.51x | 1.12x | 0.95x | 0.94x | 0.69x | 0.57x | 0.55x |
Debt / EBITDA | 7.99x | 18.12x | 5.37x | 4.62x | 4.16x | 133.90x | 3.05x | 2.85x | 3.07x |
Net Debt / EBITDA | 7.86x | 17.84x | 5.08x | 4.53x | 4.09x | 128.17x | 2.93x | 2.58x | 2.88x |
Interest Coverage | 3.03x | 0.64x | 2.98x | 3.48x | 5.08x | -0.36x | 5.11x | 6.97x | 7.31x |
Total Equity | 1.18B▲ 0% | 1.1B▼ 7.0% | 1.17B▲ 6.9% | 1.36B▲ 16.0% | 1.58B▲ 16.1% | 1.45B▼ 8.3% | 1.66B▲ 14.4% | 1.83B▲ 10.9% | 1.89B▲ 2.9% |
Equity Growth % | 43.29% | -7.02% | 6.86% | 16% | 16.15% | -8.27% | 14.37% | 10.86% | 2.87% |
Book Value per Share | 22.02 | 21.05 | 22.90 | 26.84 | 31.03 | 29.01 | 32.98 | 36.64 | 38.74 |
Total Shareholders' Equity | 1.18B | 1.1B | 1.17B | 1.36B | 1.58B | 1.45B | 1.66B | 1.83B | 1.89B |
Common Stock | 534K | 536K | 538K | 540K | 544K | 548K | 555K | 560K | 562K |
Retained Earnings | 736.28M | 701.82M | 844.1M | 1.01B | 1.21B | 1.13B | 1.34B | 1.56B | 1.75B |
Treasury Stock | -7.67M | -59.93M | -117.62M | -130.73M | -133.65M | -189.11M | -219.62M | -277.21M | -439.3M |
Accumulated OCI | -19.32M | -25.75M | -44.16M | -19.8M | -19.03M | -31.56M | -34.49M | -37.66M | -28.37M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PBH Cash Flow Statement
Prestige Consumer Healthcare Inc. (PBH) cash flow — operating, investing & free cash flow history
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 210.11M | 189.28M | 217.12M | 235.61M | 259.92M | 229.72M | 248.93M | 251.51M | 265.41M |
Operating CF Margin % | 20.18% | 19.4% | 22.55% | 24.98% | 23.92% | 20.37% | 22.12% | 22.11% | 24.38% |
Operating CF Growth % | 42.19% | -9.91% | 14.71% | 8.51% | 10.32% | -11.62% | 8.36% | 1.04% | 5.52% |
Net Income | 339.57M | -35.8M | 142.28M | 164.68M | 205.38M | -82.31M | 209.34M | 214.6M | 190.3M |
Depreciation & Amortization | 33.43M | 31.78M | 29M | 30.16M | 32.09M | 32.63M | 30.68M | 30.17M | 31.27M |
Stock-Based Compensation | 8.91M | 7.44M | 7.64M | 8.54M | 9.04M | 12.4M | 14.01M | 11.16M | 0 |
Deferred Taxes | -269.09M | -40.55M | 13.85M | 18.63M | 9.98M | -60.77M | 23.07M | 0 | 22.7M |
Other Non-Cash Items | 113.05M | 234.74M | 15.55M | 19.19M | 14.38M | 381.61M | 11.66M | 37.52M | 30.98M |
Working Capital Changes | -15.76M | -8.32M | 8.8M | -5.6M | -10.95M | -53.85M | -39.83M | -41.94M | -9.84M |
Change in Receivables | -5.04M | -2.98M | -2.85M | 36.87M | -24.65M | -24.93M | -6.32M | -16.33M | -3.69M |
Change in Inventory | -2.48M | -10.54M | 2.93M | 2.97M | 663K | -42.23M | 24.44M | -9.31M | -1.6M |
Change in Payables | -10.03M | -3.99M | 6.21M | -17.34M | 9.15M | 7.26M | -24.97M | -19.41M | -151K |
Cash from Investing | -11.56M | 55.43M | -16.57M | -22.24M | -256.51M | -11.58M | -20.11M | -17.45M | -136.84M |
Capital Expenditures | -12.53M | -10.48M | -14.56M | -22.24M | -9.64M | -7.78M | -9.55M | -8.22M | -11.18M |
CapEx % of Revenue | 1.2% | 1.07% | 1.51% | 2.36% | 0.89% | 0.69% | 0.85% | 0.72% | 1.03% |
Acquisitions | 0 | 65.91M | -2.76M | 0 | -246.87M | -3.8M | -10.56M | -9.23M | -123.74M |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 970K | 65.91M | 750K | 0 | 0 | 0 | 0 | 0 | -1.93M |
Cash from Financing | -208.96M | -249.33M | -131.43M | -279.42M | -7.57M | -185.85M | -241.01M | -182.07M | -163.84M |
Debt Issued (Net) | -209M | -200M | -68.48M | -251.44M | -5.58M | -137.75M | -227.83M | -139.54M | -7.28M |
Equity Issued (Net) | 0 | -47.05M | -56.72M | -11.87M | 0 | -50M | -25M | -36.71M | -152M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -1.07M | -49.98M | -56.72M | -11.87M | 0 | -50M | -25M | -51.51M | -156.28M |
Other Financing | 45K | -2.28M | -6.23M | -16.11M | -1.99M | 1.91M | 11.81M | -5.83M | -4.57M |
Net Change in Cash | -9.31M▲ 0% | -5.02M▲ 46.1% | 67.23M▲ 1439.8% | -62.46M▼ 192.9% | -5.12M▲ 91.8% | 31.3M▲ 711.8% | -12.02M▼ 138.4% | 51.41M▲ 527.7% | -34.02M▼ 166.2% |
Free Cash Flow | 197.58M▲ 0% | 178.8M▼ 9.5% | 202.56M▲ 13.3% | 213.36M▲ 5.3% | 250.28M▲ 17.3% | 221.93M▼ 11.3% | 239.38M▲ 7.9% | 243.29M▲ 1.6% | 254.23M▲ 4.5% |
FCF Margin % | 18.98% | 18.32% | 21.03% | 22.62% | 23.03% | 19.68% | 21.27% | 21.38% | 23.35% |
FCF Growth % | 36.45% | -9.5% | 13.29% | 5.33% | 17.3% | -11.33% | 7.86% | 1.64% | 4.5% |
FCF per Share | 3.69 | 3.43 | 3.96 | 4.22 | 4.92 | 4.45 | 4.77 | 4.86 | 5.22 |
FCF Conversion (FCF/Net Income) | 0.62x | -5.29x | 1.53x | 1.43x | 1.27x | -2.79x | 1.19x | 1.17x | 1.39x |
Interest Paid | 98.57M | 98.23M | 92.17M | 80.29M | 61.36M | 54.24M | 63.25M | 47.8M | 0 |
Taxes Paid | 24.44M | 32.8M | 30.6M | 34.38M | 46.57M | 40.74M | 59.64M | 52.12M | 0 |
PBH Key Ratios
Prestige Consumer Healthcare Inc. (PBH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 8.86% | 33.94% | -3.15% | 12.55% | 13.02% | 13.99% | -5.44% | 13.5% | 12.3% | 10.22% |
Return on Invested Capital (ROIC) | 5.8% | 5.3% | 1.69% | 7.65% | 7.85% | 8.39% | -0.58% | 9.33% | 9.14% | 8.21% |
Gross Margin | 56.72% | 55.37% | 56.94% | 57.34% | 58.03% | 57.11% | 55.45% | 55.49% | 55.76% | 52.78% |
Net Margin | 7.87% | 32.61% | -3.67% | 14.77% | 17.46% | 18.9% | -7.3% | 18.6% | 18.86% | 17.48% |
Debt / Equity | 2.67x | 1.69x | 1.64x | 1.51x | 1.12x | 0.95x | 0.94x | 0.69x | 0.57x | 0.55x |
Interest Coverage | 2.18x | 3.03x | 0.64x | 2.98x | 3.48x | 5.08x | -0.36x | 5.11x | 6.97x | 7.31x |
FCF Conversion | 2.13x | 0.62x | -5.29x | 1.53x | 1.43x | 1.27x | -2.79x | 1.19x | 1.17x | 1.39x |
Revenue Growth | 9.4% | 18.04% | -6.28% | -1.31% | -2.04% | 15.21% | 3.76% | -0.21% | 1.1% | -4.31% |
Related:PBH Dividend History·PBH Revenue History·PBH Price History·PBH P/E History·PBH Financial Ratios·PBH Institutional Holders
PBH SEC Filings & Documents
Prestige Consumer Healthcare Inc. (PBH) SEC filings — annual & quarterly reports (10-K, 10-Q)
PBH Frequently Asked Questions
Prestige Consumer Healthcare Inc. (PBH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Prestige Consumer Healthcare Inc. (PBH) reported $1.09B in revenue for fiscal year 2026. This represents a 12479% increase from $8.7M in 2001.
Prestige Consumer Healthcare Inc. (PBH) saw revenue decline by 4.3% over the past year.
Yes, Prestige Consumer Healthcare Inc. (PBH) is profitable, generating $190.3M in net income for fiscal year 2026 (17.5% net margin).
Dividend & Returns
Prestige Consumer Healthcare Inc. (PBH) has a return on equity (ROE) of 10.2%. This is reasonable for most industries.
Prestige Consumer Healthcare Inc. (PBH) generated $254.2M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.